By Kim Richters

The European Commission has approved Bavencio in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma, Merck KGaA (MRK.XE) said late Monday.

The drug's approval was based on positive interim results from the phase 3 study Javelin Renal 101, the German pharmaceutical company said.

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

October 29, 2019 02:48 ET (06:48 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck KGaA (PK) Charts.